In Brief: Tri-Med PYtest
This article was originally published in The Gray Sheet
Executive SummaryTri-Med PYtest: Carbon-14 urea breath test for diagnosis of Helicobacter pylori is awaiting final FDA approval following March 7 submission of package insert clarifications requested by the agency in its Feb. 27 approvable letter to the firm. During February 1996 review of a new drug application for the test, FDA's Gastrointestinal Drugs Advisory Committee indicated that a confirmatory study of the diagnostic was inadequate because it did not generate appropriate control information ("The Gray Sheet" March 4, 1996, p. 17). Tri-Med says it submitted data on additional patients last fall to correct the deficiency...
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.